Diversified Trust Co Has $785,000 Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Diversified Trust Co increased its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 6.3% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 66,633 shares of the biopharmaceutical company’s stock after purchasing an additional 3,938 shares during the period. Diversified Trust Co’s holdings in Amicus Therapeutics were worth $785,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC boosted its stake in shares of Amicus Therapeutics by 812.1% during the 1st quarter. Los Angeles Capital Management LLC now owns 118,360 shares of the biopharmaceutical company’s stock valued at $1,394,000 after buying an additional 105,384 shares during the period. Healthcare of Ontario Pension Plan Trust Fund boosted its stake in shares of Amicus Therapeutics by 15.6% during the 4th quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 318,500 shares of the biopharmaceutical company’s stock valued at $4,520,000 after buying an additional 43,000 shares during the period. Vanguard Group Inc. boosted its stake in shares of Amicus Therapeutics by 5.0% during the 4th quarter. Vanguard Group Inc. now owns 28,492,486 shares of the biopharmaceutical company’s stock valued at $404,308,000 after buying an additional 1,360,613 shares during the period. Wellington Management Group LLP boosted its stake in shares of Amicus Therapeutics by 101.9% during the 4th quarter. Wellington Management Group LLP now owns 15,190,024 shares of the biopharmaceutical company’s stock valued at $215,546,000 after buying an additional 7,666,335 shares during the period. Finally, American International Group Inc. raised its holdings in shares of Amicus Therapeutics by 0.9% during the 4th quarter. American International Group Inc. now owns 141,249 shares of the biopharmaceutical company’s stock valued at $2,004,000 after purchasing an additional 1,298 shares in the last quarter.

Amicus Therapeutics Stock Performance

NASDAQ FOLD opened at $9.85 on Wednesday. The company has a debt-to-equity ratio of 2.97, a current ratio of 3.03 and a quick ratio of 2.61. The firm has a market capitalization of $2.92 billion, a price-to-earnings ratio of -20.10 and a beta of 0.71. The company’s fifty day moving average is $9.95 and its two-hundred day moving average is $11.66. Amicus Therapeutics, Inc. has a 52-week low of $9.02 and a 52-week high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.04. The company had revenue of $110.40 million for the quarter, compared to analyst estimates of $111.19 million. Amicus Therapeutics had a negative net margin of 34.73% and a negative return on equity of 77.08%. The business’s quarterly revenue was up 27.9% on a year-over-year basis. During the same period last year, the business posted ($0.18) EPS. Equities research analysts forecast that Amicus Therapeutics, Inc. will post -0.12 EPS for the current year.

Insiders Place Their Bets

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $10.07, for a total value of $75,525.00. Following the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,928,605.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.20% of the company’s stock.

Analysts Set New Price Targets

FOLD has been the topic of a number of recent research reports. JPMorgan Chase & Co. cut their price target on shares of Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Monday, March 18th. Guggenheim upgraded shares of Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target on the stock in a report on Tuesday, May 14th. Wells Fargo & Company initiated coverage on shares of Amicus Therapeutics in a report on Thursday, May 30th. They set an “overweight” rating and a $18.00 price target on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Friday, May 10th. Finally, UBS Group dropped their target price on shares of Amicus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a report on Friday, May 10th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Amicus Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $17.57.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.